Strategic Plan
2015-2017

Building Resilience for Sustainable Growth

May 27, 2015
Astellas Pharma Inc.
President and CEO
Yoshihiko Hatanaka
Cautionary Statement Regarding Forward-Looking Information

This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.

Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company’s intellectual property rights and the adverse outcome of material litigation.

This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations, promote unapproved uses in any fashion nor provide medical advice of any kind.
Review of FY2014 Mid-term Management Plan

Consistent implementation of Growth & Efficiency strategies; Growth trend re-established through continuous launch of new products

- Established a regenerative medicine unit
- Seized external opportunities (biotechs and academia)
- Formed compound library sharing partnership with Daiichi Sankyo
- Reshaped research organization
- Established the department of Astellas Innovation Management (AIM)
- Established the department of Evolving Medical Solutions
- Began strategic alliance with Amgen
- Enhance further global functions of regulatory affairs, regulatory assurance and quality assurance
- Acquired Perseid
- In-licensed ASP0113
- Acquired OSI (acquired Tarceva)
- In-licensed fidaxomicin
- Initiated new initiative for “Multi-track R&D”

Product launch

2014
Suglat

2013
VESOMNI
Acofide
ASTAGRAF
Bisono Tape

2012
ARGAMATE*
DIFICLIR
Feburic
Kiklin
Regnite
XTANDI
Quattrovac
Gonax
Cimzia

2011
ENCEVAC
Betanis

2010
Micamlo

*Initiation of sales promotion activities

- Closed Hasune Office and consolidated in Nihonbashi
- Transferred Fuji Plant to Nichii-ko
- Business process outsourcing to Accenture in multiple business areas
- Closed OSI/Perseid; downsized ARIA
- Withdrew from in-house fermentation drug discovery research
- Out-licensed ASP015K (excluding Japan)
- Closed Urogenix
- Terminated development of Factor Xa inhibitor
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Changes Impacting New Drug Businesses

**Drivers**

- Scientific progress
- Existing high UMNs*
- Emergence of new modalities and drug-discovery technologies
- Emergence of diverse medical solutions
- Accelerated approval processes
- Continued market growth

**Challenges**

- Healthcare cost containment
- Increased influence of payers
- Increased requirement for approvals
- Finite product life cycle

* UMNs: unmet medical needs
Opportunities to pursue

Innovative drug discovery in TAs* with high UMNs

New modalities such as cell therapies, gene therapies, etc.

Increasing number of technologies with applicability in various fields

Opportunities to create innovative value for patients still exist

* TAs: Therapeutic Areas
VISION

Turn innovative science into value for patients on the forefront of healthcare change

Turn changes into opportunities:
Create innovative new drugs and medical solutions by leveraging our core capabilities

Go beyond GCL*:
Identify business opportunities continuously by embracing healthcare changes with multiple perspectives

*GCL: Global Category Leader
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Achieving Sustainable Growth

New products will drive mid-term growth; Sustainable growth will be reinforced by continuous selective investment in innovation and strengthening of the business foundation.

Creating Innovation

Maximizing the Product Value

Enhancing Capabilities to Deliver Innovative Medicines

Advancing into New Opportunities

Explore and capture external business opportunities through acquisition, collaboration, and in-licensing.

Pursuing Operational Excellence

Sales

FY14 FY15 FY16 FY17
1. **VISION**

2. **Strategic Plan 2015-2017**
   I. Strategy
      - Maximizing the Product Value
      - Creating Innovation
        - Enhancing Capabilities to Deliver Innovative Medicines
        - Advancing into New Opportunities
      - Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Maximizing the Product Value

New products will drive both mid-term growth and growth longer term after patent expiry of Vesicare and Tarceva

- Expand the ratio of sales coming from new products during this strategic plan period
- Reduce reliance on products with patents expiring by 2020

Composition ratio to total net sales:

- **16%** Key new products*
- **30%** Key products with patents expiring by 2020
- **54%** Others

*Betanis/ Myrbetriq/ BETMIGA, XTANDI, Cimzia, Suglat, CRESEMB

*For illustrative purposes only
Drive rapid market penetration of Betanis/ Myrbetriq/ BETMIGA and establish its position as a new therapeutic option for OAB* treatment

Maximizing the OAB franchise value

- Accelerate market penetration by Betanis/ Myrbetriq/ BETMIGA
  - Launch in more than 70 countries by 2016
  - Differentiate by superior balance between efficacy and tolerability with unique mode-of-action to establish its position as a new therapeutic option for OAB treatment
  - Expand into combination treatment with Vesicare
  - Conduct post-marketing studies on adherence, in combination, and important sub-populations such as ‘elderly’

- Further reinforcement of Vesicare as the first choice of anti-muscarinic drug
  - Continue to build on the trusted profile of Vesicare through the abundance of clinical data and experience

OAB Franchise Global sales CAGR (%): High single-digit

188.4 bn JPY

FY14 FY17

Vesicare
Betanis/ Myrbetriq/ BETMIGA

*For illustrative purposes only

*OAB: Overactive bladder

Copyright © 2015 Astellas Pharma Inc.
Maximizing the Product Value: Oncology Franchise

Maximize XTANDI rapidly in the chemo-naive indication, and pursue long-term growth by expanding indications

Oncology Franchise Global sales
CAGR (%): mid twenties

Expand sales geographies
- Post chemo indication: Expand geographies with a focus on emerging markets
- Chemo-naive indication: Ensure successful launch of PREVAIL and obtain reimbursement

Establish a market-leader position in chemo-naive indication
- Differentiate by superior product profile including administration conditions with fewer restrictions and good tolerability in addition to the efficacy for the overall survival as demonstrated by the PREVAIL trial
- Utilize our strong presence in the urology field

Expand indications
- Expand indications to earlier stage prostate cancer (M0 CRPC, M0 BCR)
- Pursue indications in other tumor types, such as breast cancer and hepatocellular carcinoma (HCC)

FY14 FY17

208.4 bn JPY

*For illustrative purposes only

Copyright © 2015 Astellas Pharma Inc.
# Maximizing the Product Value: XTANDI Development Progress

## Studies to build value of XTANDI progress steadily

<table>
<thead>
<tr>
<th>Study Phase/Region*</th>
<th>Target</th>
<th>Design</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P3 EU/US/Asia [PROSPER study]</td>
<td>M0 CRPC Non-metastatic CRPC</td>
<td>Placebo-controlled, n=1,500</td>
<td></td>
<td></td>
<td></td>
<td>First Patient In: Nov. 2013</td>
</tr>
<tr>
<td>P3 EU/US/Asia [EMBARK study]</td>
<td>M0 BCR Non-metastatic prostate cancer, biochemical recurrence</td>
<td>To compare with ADT and combination, n=1,860</td>
<td></td>
<td></td>
<td></td>
<td>First Patient In: Jan. 2015</td>
</tr>
<tr>
<td>P2 EU/US [TERRAIN study]</td>
<td>Pre-chemo Metastatic CRPC</td>
<td>To compare with bicalutamide, n=375</td>
<td></td>
<td></td>
<td></td>
<td>Presented data at EAU</td>
</tr>
<tr>
<td>P2 US [STRIVE study]</td>
<td>Pre-chemo Metastatic or non-metastatic CRPC</td>
<td>To compare with bicalutamide, n=400</td>
<td></td>
<td></td>
<td></td>
<td>Presented data at AUA</td>
</tr>
<tr>
<td>P2 US</td>
<td>Neoadjuvant therapy Undergoing prostatectomy</td>
<td>Monotherapy or combo with leuprolide or dutasteride, n=50</td>
<td></td>
<td></td>
<td></td>
<td>Obtained data</td>
</tr>
<tr>
<td><strong>Breast Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2 US/EU</td>
<td>Triple-negative Advanced, androgen receptor-positive, triple-negative breast cancer</td>
<td>Open-label, n=118</td>
<td></td>
<td></td>
<td></td>
<td>Plan to present full data at ASCO</td>
</tr>
<tr>
<td>P2 US/EU</td>
<td>ER/PgR positive Advanced breast cancer that is ER positive or PgR positive and HER2 normal</td>
<td>Placebo-controlled, in combination with exemestane, n=240</td>
<td></td>
<td></td>
<td></td>
<td>Last Patient In: Mar. 2015</td>
</tr>
<tr>
<td>P2 US/EU</td>
<td>HER2 positive Advanced, androgen receptor-positive, HER2 positive/ER negative breast cancer</td>
<td>Open-label, n=80</td>
<td></td>
<td></td>
<td></td>
<td>First Patient In: Sep. 2014</td>
</tr>
<tr>
<td><strong>HCC</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2 US/EU</td>
<td>Hepatocellular carcinoma (HCC)</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td>In preparation</td>
</tr>
</tbody>
</table>

ADT: Androgen-deprivation therapy, ER: Estrogen receptor, PgR: Progesterone receptor, HER2: Human epidermal growth factor receptor 2 
AUA: American Urological Association, EAU: European Association of Urology, ASCO: American Society of Clinical Oncology

**The region where the study is performed**
Maximizing the Product Value: Other Therapeutic Areas

Maintain our leadership position in the transplant field; Pursue local value maximization of new products by driving sales through focused resource prioritization

**Maintain the Tacrolimus franchise**
- Pursue further growth of Graceptor/Advagraf/Astagraf XL/Prograf XL
- Continuous growth by the expansion of market and indications in emerging markets mainly in Asia

**Tacrolimus Global sales**
- CAGR (%): minus low single-digit
- $194.7$ bn JPY

**Maximizing value in other fields**

- **Ensure the uptake of Suglat (Japan)**
  - Continue to obtain No.1 market share in the SGLT2 market
  - Execute a large-scale post-marketing survey (elderly and long-term tests)
  - Develop combination product with DPP-4 inhibitor

- **Prepare launch for collaborative products with Amgen (evolocumab and romosozumab etc.) (Japan)**
  - Start Amgen Astellas BioPharma sales organization

- **Ensure steady market penetration of CRESEMBA (U.S.)**
Sales by Region

Improving balance of sales across key regions with growth of US, EMEA and Asia/Oceania portions, and continuation of Japan sales growth

Global and regional sales CAGR (%)

<table>
<thead>
<tr>
<th>Region</th>
<th>Sales CAGR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>Marginal increase</td>
</tr>
<tr>
<td>Americas</td>
<td>High single-digit</td>
</tr>
<tr>
<td>EMEA</td>
<td>High single-digit</td>
</tr>
<tr>
<td>Asia/Oceania</td>
<td>Mid teens</td>
</tr>
</tbody>
</table>
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Enhancing Capabilities to Deliver Innovative Medicines

Creating innovative drugs efficiently through optimal resource allocation and active acquisition of innovative science

Network Research System

Greater utilization of external R&D resources

Take on challenges in new therapeutic areas and drug discovery technologies

Best Science

Best Talent

Best Place

F A S T E N (FAST-Ex-New-standard)

FAST TRACK

Highest resource priority

NEW STANDARD TRACK

Fastest POC

Utilize external resources

Ex. TRACK

POC*

Launch

*POC: Proof of Concept
Prioritize disease areas for research focus by following aspects

- Changes of unmet medical needs
- The latest feasibility for research and development

**Focused Disease Areas for Research**

**Existing TAs**: Urology, Oncology, Immunology, Nephrology, Neuroscience

**New TAs**: Muscle Diseases, Ophthalmology

*TA: Therapeutic Area*
**Development Project and Research Approach by TA: Urology**

---

### Post-POC Project

**Maximize OAB franchise**
- Pursue pediatric indication for Vesicare and Myrbetriq/Betmiga
- Pursue development of EB178

---

### Pre-POC Project & Research Approach

**Build a next generation franchise by addressing new urology disorders with high unmet medical needs**
- Nocturia with nocturnal polyuria (ASP7035*)
- Stress urinary incontinence (ASP2205, ASP5633)
- Underactive bladder (ASP6282)

---

*Development by Drais as a part of activities of "Multi-Track R&D". MultiTrack: multi-tracking of the research and development process*
Development Project and Research Approach by TA: Oncology

Seek additional indications for XTANDI, advance development of ASP2215 and ASP8273; in the long-term, transform research approach to create a highly competitive pipeline.

**Post-POC Project**

- Advance the development of XTANDI for early stage prostate cancer
  - Aim to expedite Phase 3 results
- Advance the development of ASP2215
  - Aim to accelerate launch of ASP2215 for AML as a FLT3/AXL inhibitor

**Pre-POC Project & Research Approach**

- Obtain POC of XTANDI for breast cancer and hepatocellular carcinoma (HCC)
- Approach to intractable cancers with Precision Medicine
  - Approach to target EGFR active mutation / resistant mutation for NSCLC (ASP8273)
  - Approach to target FGFR aberrant signal / genetic mutation for intractable cancer indications (hepatocellular cancer and bladder cancer, etc.) (ASP5878)
  - ADC projects that target specific antigen (AGS-16C3F and ASG-22ME, etc.)
- Drug discovery research with novel approaches including cancer immunology and cancer metabolism to tackle cancer indications or patient populations which do not respond to existing therapies
  - Creation of novel cancer immunology portfolio (collaboration with Potenza, etc.)
  - T cell receptor-like mAb (h8F4) targeting a conformational epitope of PR1/HLA-A2 (collaboration with MD Anderson)
  - Modulating energy generation through oxidative phosphorylation in mitochondria in cancer cell (ASP4132)
  - Modulating autophagy in cancer cell (collaboration with Cancer Research UK)
  - K-RAS inhibitor (collaboration with Dana-Farber Cancer Institute)

AML: acute myeloblastic leukemia, ADC: antibody-drug conjugate
**Development Project and Research Approach by TA: Immunology**

Explore targets for new drug discoveries that involve several immune disorders and engage in drug creation with the aim of developing a causal treatment/cure for immune disorders.

**Post-POC Project**

- **Advance the development of ASP015K**
  - Aim to strengthen product portfolio in immunology with early launch for rheumatoid arthritis

**Pre-POC Project & Research Approach**

- **Create immune disorder drugs that achieve causal treatment/cure, or significant improvement of symptoms**
  - Development of therapeutic vaccine for Japanese Red Cedar Pollinosis (ASP4070/JRC2-LAMP-vax)
  - Develop rheumatoid arthritis drug targeting synovial cells (ASP5094)

- **Discover next generation innovative immuno-modulating drugs**
  - Aim to discover drugs addressing several immune-related disorders (AK projects)
Development Project and Research Approach by TA: Nephrology & Neuroscience

In nephrology, aim to launch roxadustat as first-in-class and prove the efficacy of development projects in early stage;
In neuroscience, aim to obtain POC for development projects in early stage

Post-POC Project

[Nephrology]

Advance the development of roxadustat
• Aim to launch as the first in class novel mechanism for oral treatment of anemia of CKD

Pre-POC Project & Research Approach

[Nephrology]

Seek to develop first-in-class drugs for kidney diseases with high unmet needs
• Aim for preventing albuminuric and proteinuric, slowing reduction of renal function and delaying time to dialysis in diabetic nephropathy by suppressing low grade inflammation and oxidant stress in kidney (ASP8232)
• Approach to prevent progression of chronic kidney disease by reducing glomerular load and suppressing accumulation of uremic toxins (ASP6858)

Advance the drug discovery research focusing on damage for glomerular and renal tubular epithelial cells in kidney

[Neuroscience]

Explore psycho-neurologic diseases and pain with high unmet medical needs through drugs with new mechanism of action
• Neuropathic pain (ASP8477, ASP3662)
• Osteoarthritis pain, chronic low back pain (ASP7962)
• Cognitive impairment associated with schizophrenia (ASP4345)

Identify first-in-class drugs through collaboration with the Lieber Institute for Brain Development
Main Development Projects in Existing TAs

Continue pursuit of multiple development projects to drive sustainable growth

High potential
Pre-POC Project

<table>
<thead>
<tr>
<th>Stage</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urology</td>
<td>ASP5633 (Stress urinary incontinence)</td>
<td>ASP7035 (Nocturia) *</td>
<td>EB178 (OAB)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASP2205 (Stress urinary incontinence)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASP6282 (Underactive bladder)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>ASP5878 (Cancer)</td>
<td>ASP8273 (NSCLC)</td>
<td>enzalutamide (M0 CRPC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASP4132 (Cancer)</td>
<td>enzalutamide (Breast cancer)</td>
<td>enzalutamide (M0 BCR)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>enzalutamide (HCC)</td>
<td>ASP2215 (AML)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>ASP5094 (RA)</td>
<td>ASP8477 (Neuropathic pain)</td>
<td>ASP015K (RA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASP6858 (CKD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASP7962 (Osteoarthritis pain, Chronic low back pain)</td>
<td>ASP3662 (Diabetic nephropathy)</td>
<td>roxadustat (Anemia associated with CKD)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASP4345 (Cognitive impairment associated with schizophrenia)</td>
<td>ASP8232 (Diabetic nephropathy)</td>
<td>isavuconazonium sulfate (Candidemia)</td>
<td></td>
</tr>
</tbody>
</table>

Main Post-POC Project

<table>
<thead>
<tr>
<th>Filed</th>
<th>Expected total peak sales: around 300 billion yen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NSCLC: Non-small cell lung cancer, HCC: Hepatocellular carcinoma, M0 CRPC: Non-metastatic castration-resistant prostate cancer, M0 BCR: Non-metastatic biochemical recurrence, AML: Acute myeloid leukemia, CKD: Chronic kidney disease, RA: Rheumatoid arthritis,</td>
</tr>
</tbody>
</table>

※Approval may not be achieved and the approved indications may be different from this slide.

※Development by Drais as a part of activities of “Multi-Track R&D”.

Copyright © 2015 Astellas Pharma Inc.
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Advancing into New Opportunities

Explore new opportunities in research for developing new drugs in new therapeutic areas and new technologies/new modalities.

Innovative medical solutions by combining variety of internal and external healthcare capabilities

New therapeutic areas
(Muscle Diseases, Ophthalmology etc.)

Rx business

Existing therapeutic areas
(Urology, Oncology, Immunology, Nephrology, Neuroscience)

New technologies/New modalities
(Regenerative medicine, Next-generation vaccine etc.)

Advancing into New Opportunities
Advancing into New Opportunities (Part 1)

Accelerate drug discovery research in new therapeutic areas as potential candidates for the next-focus;
Continue investment in innovation to achieve long-term growth by leveraging external partnerships

New TAs

- Designate Muscle Diseases and Ophthalmology to the focused disease areas for research
  - Aim to explore new drugs with high UMN for preventing progress of diseases or achieving causal therapies in muscle diseases (Cytokinetics, Mitobridge)
  - Focus on posterior eye segment in ophthalmology (Retinitis pigmentosa: Constance L. Cepko, Ph. D., Harvard Medical School)
- Further exploration of future research focus

Next-Generation Vaccine

- Develop a preventive vaccine against RSV (ClearPath)
- Develop a vaccine as a causal therapy for Japanese Red Cedar Pollinosis (Immunomic)

Stage

<table>
<thead>
<tr>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-POC Project</td>
<td>Post-POC Project</td>
<td>Mitobridge Collaboration</td>
<td>CK-2127107 (Spinal muscular atrophy)</td>
</tr>
<tr>
<td>New TAs Muscle Diseases</td>
<td>New TAs Ophthalmology</td>
<td>Harvard Medical School Collaboration (Retinitis pigmentosa)</td>
<td>ASP0113 (SOT)</td>
</tr>
<tr>
<td>Next-generation vaccine CMV prevention</td>
<td>Next-generation vaccine RSV prevention</td>
<td>ClearPath Collaboration</td>
<td>ASP4070/ JRC2-LAMP-vax</td>
</tr>
</tbody>
</table>

CMV: Cytomegalovirus, RSV: Respiratory syncytial virus, HCT: Hematopoietic cell transplant, SOT: Solid organ transplant
Advancing into New Opportunities (Part 2)

Accelerate research of cell therapy as a new modality; Develop new opportunities through leveraging internal strengths and external healthcare capabilities to create innovative medical solutions

Regenerative Medicine (Cell Therapy)

- Established Regenerative Medicine Labs. (April 2015)
  - Targeting areas with high unmet medical needs, such as cardiovascular disease and cancer
  - Stem cell formulation (Start the first clinical trial within a few years)
- Set joint research chair with Osaka Univ. for next-generation cell therapies (January 2015)
  - Development of technologies to make transfused/transplanted cells highly functional and to enhance their therapeutic effects through optimization of the sources of transfused/transplanted cells

Evolving Medical Solutions

- Identify multiple projects and start clinical trials of the first project during the period of this management plan. Anticipate contribution to profits roughly from around 2020.
  - Provide more accurate early diagnosis methods for localized primary tumor and micro-metastasis, etc. (make use of antibody technology)
  - Provide products that will contribute to reduction of surgery time and better outcome (hemostatic agent and pain management after surgery, etc.)

Drug repurposing

- Established a department of Drug Repurposing & Application Management aiming at the development for new indications by applying new scientific approach to terminated products and launched products (April 2015)
- Promote the research and development of 5 compounds in other indications by localized administration with new technologies
R&D Investment Allocation Philosophy

Maintain investment in existing TAs and ensure sufficient investment in new opportunities

Now

Future

New opportunities*

Existing TAs

Investment scale: More than 17% of sales

New opportunities: new TAs (Muscle Diseases and Ophthalmology, etc.),
new technologies/modalities (regenerative medicine and next-generation vaccines, etc.)
+ innovative medical solutions by combining variety of internal and external healthcare capabilities

*For illustrative purposes only
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Pursuing Operational Excellence

Create organizations and systems that can flexibly respond to rapidly changing environments and work toward higher quality and efficiency of operations.

Key initiatives during strategic plan period
- Proactive and high-quality actions for pharmacovigilance initiatives
- Strengthen corporate disclosure mechanism including further actions for transparency
- Continuous resource allocation for the functions driving our competitive advantage
- Review and optimize our business platform and cost structure continuously
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Financial Guidance

Maximize profits

- ROE*: 15% or more
  - Maintain and improve this level after the strategic plan period

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Consolidated Sales</td>
<td>CAGR (%): Mid single-digit</td>
</tr>
<tr>
<td>Core Operating Profit</td>
<td>CAGR that exceeds sales' CAGR</td>
</tr>
<tr>
<td>R&amp;D Expenses</td>
<td>Higher than 17% against sales</td>
</tr>
</tbody>
</table>

| Core EPS              | CAGR that exceeds CAGR of core operating profit |
| DOE                  | 6% or more |

<table>
<thead>
<tr>
<th>FY14</th>
<th>FY17</th>
</tr>
</thead>
<tbody>
<tr>
<td>COG+SG&amp;A+ Amortisation</td>
<td>Optimal allocation of management resources</td>
</tr>
<tr>
<td>R&amp;D Expenses</td>
<td>Core Operating Profit</td>
</tr>
</tbody>
</table>

Sustainable sales growth
Continue investing in R&D for growth
Further improvement of operating profit ratio

Generate cash to support growth and enhance capital efficiency

- Pursue balance sheet management (Maximize free cash flows)
- Continuous improvement of shareholder returns

*For illustrative purposes

*Full basis
Profit Distribution Policy

1. Top priority on investment for growth of Rx business

2. Dividends to be increased continuously based on mid- and long-term growth

3. Share buybacks to be implemented in a flexible manner
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Creating Social Value

Solve problems related to Access to Health, harnessing our strengths and taking advantage of partnerships with other organizations

Resolve social issues and enhance our corporate reputation over the long-term

Joint drug-discovery research for NTDs

Core business activities

Development of Pediatric Formulation for Schistosomiasis

NTDs: Neglected Tropical Diseases
Further Strengthen Corporate Governance

Based on expectation and request from all stakeholders, aim at further improvement of government function including transparency, objectivity and mobility

- Increase number of outside auditors* --- Board of Directors (4 of 7) and Audit & Supervisory Board (3 of 5) comprised of more than half independent external executives

- Reorganize the global management committees and Establish an Executive Committee (No. of members reduced from 11 to 5)

- Establish a Global Risk Management Office --- Ascertain global risks and promote optimal risk management measures

- Establish a Corporate Disclosure Committee --- Target all information disclosure items including non-financial information and meet diversified expectations

*To be discussed at general shareholders’ meeting on June 17
1. VISION

2. Strategic Plan 2015-2017
   I. Strategy
      ➢ Maximizing the Product Value
      ➢ Creating Innovation
         • Enhancing Capabilities to Deliver Innovative Medicines
         • Advancing into New Opportunities
      ➢ Pursuing Operational Excellence
   II. Financial Guidance and Profit Distribution Policy
   III. Creating Social Value and Corporate Governance
   IV. Conclusion
Achieving sustainable growth

<Strategy>

1. Maximizing the Product Value
   - Maximize the value of product driving mid-term growth, such as OAB franchise and XTANDI

2. Creating Innovation
   - Prioritize investment in post-POC projects
   - Proactively seek new opportunities and ensure sufficient investment allocated to them

3. Pursuing Operational Excellence
   - Create organizations and systems that can flexibly respond to rapidly changing environments and work toward higher quality and efficiency of operations

Explore and grasp external business opportunities through acquisition, collaboration, and in-licensing

<Financial Guidance>

15% or more of ROE by maximization of profits and improvement of capital efficiency
On the Forefront of Healthcare Change